Simple fluid drain may ease breathing in heart failure
NCT ID NCT07419360
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether removing fluid from around the lungs (a procedure called thoracentesis) can reduce shortness of breath in people hospitalized for heart failure. About 216 adults will either get standard heart failure medicines alone or medicines plus the fluid removal. Researchers will measure breathlessness and quality of life right after the procedure and again at 14 and 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- thoracentesis (fluid removal procedure)
- What this could lead to
- If it works, this could provide a simple, routine procedure to quickly relieve breathlessness in heart failure patients with fluid around the lungs.
- What could go wrong
- This is a relatively small, early-stage trial (216 participants) testing a short-term symptom benefit. The procedure carries small risks like bleeding or infection, and the improvement may be modest or not last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 216 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients age \>18 years and. * Clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g., peripheral edema, pleural effusion, or ascites) and * Assessment of left ventricular ejection fraction (LVEF) by echocardiography performed during the time of index hospitalization or within 3 months prior to enrollment and * Serum NT-proBNP level of \>1000 pg/ml or Serum BNP\>250 pg/ml at the time of enrollment and * Radiographic evidence of moderate to large pleural effusion, defined as pleural fluid occupying more than 1/3rd of the hemithorax on chest X-ray. Exclusion Criteria: * Clinical indication for diagnostic thoracentesis - Presence of fever, clinical signs of infection, or atypical pleural effusion for CHF (unilateral left-sided effusion, findings suggestive of malignancy, infection, or alternative etiologies) or. * Loculated pleural effusion - Evidence of loculated pleural effusion on thoracic ultrasound, as defined as the presence of septations or complex homogenous echogenic fluid (see Imaging Assessment section) or. * Clinical indication for therapeutic thoracentesis - Presence of massive pleural effusion with acute respiratory failure requiring positive pressure ventilation, high-flow oxygen therapy (\>15 liters per minute of flow), or tension hydrothorax (massive effusion with mediastinal shift and hemodynamic compromise) or. * Contraindication to thoracentesis, uncontrolled bleeding diathesis, or irreversible INR \> 2.0 and platelet count \<50,000 or. * Patient with mechanical mitral valve, where anticoagulation cannot be safely held or. * Pleural procedure, such as but not limited to thoracentesis, chest tube placement, or thoracoscopy, within 3 months prior to enrollment or. * Cardiac or thoracic surgery within 3 months prior to enrollment or. * Requirement for chronic renal replacement therapy, such as hemodialysis or peritoneal dialysis or. * Pregnancy or * Inability or unwillingness to provide informed consent, or current incarceration (prisoners).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Congestive heart failure(CHF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Albany Medical Center
RECRUITINGAlbany, New York, 12211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple foot pump ease leg swelling in hospital patients?
- Ultrasound-Guided fluid removal may offer safer relief for overloaded kidneys
- New blood test score could personalize heart failure diuretic use
- Paramedics test handheld ultrasound to spot heart failure in the field
- AI tool aims to tailor diuretic doses for heart failure patients
- Heart failure in women: could a social worker be the missing prescription?